Financial reports
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
28 Mar 24
8-K
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
9 Nov 23
8-K
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
2 Nov 23
8-K
Departure of Directors or Certain Officers
2 Oct 23
8-K
Departure of Directors or Certain Officers
20 Sep 23
8-K
Departure of Directors or Certain Officers
13 Sep 23
8-K
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
10 Aug 23
8-K
Departure of Directors or Certain Officers
21 Jun 23
8-K
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
11 May 23
8-K
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
1 May 23
Registration and prospectus
S-8
Registration of securities for employees
10 Aug 23
424B3
Prospectus supplement
8 Jun 23
D
Indefinite amount in equity / options / securities to be acquired, sold $35.00 mm, 38 investors
22 May 23
S-3
Shelf registration
18 May 23
S-3/A
Shelf registration (amended)
21 May 21
S-8
Registration of securities for employees
9 Apr 21
S-3
Shelf registration
31 Mar 21
424B2
Prospectus for primary offering
22 Dec 20
S-3
Shelf registration
11 Dec 20
D
$108.14M in equity, sold $108.14M, 35 investors
25 Sep 20
Proxies
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
10 Dec 20
DEF 14A
Definitive proxy
20 Nov 20
PRER14A
Preliminary revised proxy
13 Nov 20
PRE 14A
Preliminary proxy
23 Oct 20
Other
EFFECT
Notice of effectiveness
5 Jun 23
CORRESP
Correspondence with SEC
31 May 23
UPLOAD
Letter from SEC
24 May 23
EFFECT
Notice of effectiveness
24 May 21
CORRESP
Correspondence with SEC
18 May 21
UPLOAD
Letter from SEC
5 Apr 21
EFFECT
Notice of effectiveness
23 Dec 20
CORRESP
Correspondence with SEC
17 Dec 20
UPLOAD
Letter from SEC
16 Dec 20
UPLOAD
Letter from SEC
20 Nov 20
Ownership
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
4
James A. Jr. Robinson
3 Oct 23
4
Allan Kirk
3 Oct 23
3
James A. Jr. Robinson
2 Oct 23
3
Allan Kirk
2 Oct 23
4
MARK N LAMPERT
9 May 23
4
Bryan E. Smith
2 May 23
4
Steven Perrin
2 May 23